簡要描述:蛋白酶調(diào)解因子7抗體注意事項;This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品分類
Product Category相關文章
Related Articles詳細介紹
商品屬性:
貨號 | 產(chǎn)品名稱 | 規(guī)格 |
GOY-01K4221 | 蛋白酶調(diào)解因子7抗體 | 50ul |
GOY-01K4221 | 蛋白酶調(diào)解因子7抗體 | 100ul |
GOY-01K4221 | 蛋白酶調(diào)解因子7抗體 | 200ul |
英文名稱: PSMD7
中文名稱: 蛋白酶調(diào)解因子7抗體
別 名;26S proteasome non ATPase regulatory subunit
7; 26S proteasome non-ATPase regulatory subunit 7; 26S proteasome regulatory
subunit rpn8; 26S proteasome regulatory subunit S12; Moloney leukemia virus 34
proviral integration; MOV 34; MOV 34L; MOV34; Mov34 homolog; Mov34 protein
homolog; MOV34L; P40 antibody Proteasome (prosome macropain) 26S subunit non
ATPase 7; Proteasome 26S non ATPase subunit 7; Proteasome 26S S12; Proteasome
subunit p40; PSD7_HUMAN; PSMD 7; PSMD-7; PSMD7; S12 antibody.
研究領域;細胞生物 信號轉(zhuǎn)導 表觀遺傳學
抗體來源;Rabbit
克隆類型;Polyclonal
交叉反應;(predicted: Human, Mouse, Rat,
Chicken, Dog, Pig, Cow, Rabbit, Sheep, )
產(chǎn)品應用;ELISA=1:5000-10000
IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200 (石蠟切片需做抗原修復)
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;37kDa
細胞定位;細胞核 細胞漿 細胞外基質(zhì) 分泌型蛋白
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH conjugated synthetic
peptide derived from human PSMD7: 31-130/324
亞 型;IgG
純化方法;affinity purified by Protein A
緩 沖 液;0.01M TBS(pH7.4) with 1% BSA,
0.03% Proclin300 and 50% Glycerol.
注意事項;This product as supplied is
intended for research use only, not for use in human, therapeutic or diagnostic
applications.
產(chǎn)品介紹 The 26S proteasome is a
multicatalytic proteinase complex with a highly ordered structure composed of 2
complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings
of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2
rings are composed of 7 beta subunits. The 19S regulator is composed of a base,
which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which
contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout
eukaryotic cells at a high concentration and cleave peptides in an
ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential
function of a modified proteasome, the immunoproteasome, is the processing of
class I MHC peptides. This gene encodes a non-ATPase subunit of the 19S
regulator. A pseudogene has been identified on chromosome 17.
Acts as a regulatory subunit of the 26S proteasome which is involved in the ATP-dependent degradation of ubiquitinated proteins.
實驗流程:
(1)特異性結(jié)合抗原:抗體本身不能直接溶解或殺傷帶有特異抗原的靶細胞,通常需要補體或吞噬細胞等共同發(fā)揮效應以清除病原微生物或?qū)е虏±頁p傷。然而,抗體可通過與病毒或毒素的特異性結(jié)合,直接發(fā)揮中和病毒的作用。
(2)活補體:IgM、IgG1、IgG2和IgG3可通過經(jīng)典途徑激活補體,凝聚的IgA、IgG4和IgE可通過替代途徑激活補體。
(3)結(jié)合細胞:不同類別的免疫球蛋白,可結(jié)合不同種的細胞,參與免疫應答。
(4)可通過胎盤及粘膜:免疫球蛋白G(IgG)能通過胎盤進入胎兒血流中,使胎兒形成自然被動
免疫。免疫球蛋白A(IgA)可通過消化道及呼吸道粘膜,是粘膜局部抗感染免疫的主要因素。
(5)具有抗原性:抗體分子是一種蛋白質(zhì),也具有刺機體產(chǎn)生免疫應答的性能。不同的免疫球蛋白分子,各具有不同的抗原性。
(6)抗體對理化因子的抵抗力與一般球蛋白相同:不耐熱,60~70℃即被破壞。各種酶及能使蛋白質(zhì)凝固變性的物質(zhì),均能破壞抗體的作用。抗體可被中性鹽類沉淀。在生產(chǎn)上常可用硫酸銨或硫酸鈉從免疫血清中沉淀出含有抗體的球蛋白,再經(jīng)透析法將其純化。
抗體的制備過程:
1.免疫原:普通的大分子蛋白,通過分子克隆構(gòu)建載體并在大腸桿菌中進行誘導表達獲得重組蛋白,純化鑒定后可直接作為免疫原;小分子蛋白或化合物等分子量小,需要偶聯(lián)載體對該分子進行改造才能使其成為具有免疫原性的抗原,常見偶聯(lián)載體如BSA、OVA、HAS等。
2. 免疫動物:常用于制備抗血清的動物有豚鼠、家兔、雞、大小鼠等,大量生產(chǎn)時需要用到狗、綿羊、山羊等。
3.免疫血清的收集:一般家兔、綿羊、山羊可采用靜動脈采血,家兔、豚鼠、大鼠、雞可采用心臟采血,家兔、山羊、綿羊可采用靜脈采血。
4. 免疫血清的純化與鑒定:得到的抗血清需要進一步的純化,利用偶聯(lián)了抗原的親和柱進行層析,具有高效,特異性強,純度高的特定。接著要鑒定純化蛋白的含量、相對分子的質(zhì)量、純度以及特異性。
5.蛋白酶調(diào)解因子7抗體免疫血清的保存:抗體一般比較穩(wěn)定,在-80℃ ~-20 ℃可以保存約5年而不會影響效價,而真空干燥保存時間可以更久。保存前需經(jīng)除菌并添加防腐劑。
產(chǎn)品咨詢
歡迎您關注我們的微信了解更多信息
電話
微信掃一掃